All Updates

Washington, D.C. – May 22, 2018 – The House of Representatives passed legislation today that, if signed into law, will create a process for accessing experimental drugs without including proper patient protections. The Senate Right-to-Try legislation (S. 204) was strongly opposed by the American Cancer Society Cancer Action Network (ACS

SPRINGDALE, Ark. – Local American Cancer Society Cancer Action Network volunteer Abbie Luzius joined more than 100 other cancer patients, survivors, caregivers, physicians and researchers in Washington, D.C., this week to urge lawmakers to make fighting cancer a top national priority. These advocates united for the 19 th annual One

American Cancer Society Cancer Action Network volunteer Courtney Hurtig, of Overland Park, joined more than 100 other cancer patients, survivors, caregivers, physicians and researchers in Washington, D.C., this week to urge lawmakers to make fighting cancer a top national priority. These advocates united as part of the 19 th annual One Voice Against Cancer lobby day to request cancer research funding at the National Cancer Institute and National Institutes of Health.

Washington, D.C. – Today the U.S. House Appropriations Committee approved an appropriations bill that would greatly restrict the Food and Drug Administration’s (FDA) authority to regulate tobacco products. The provision was attached as a rider to the FY 2019 FDA appropriations bill. A statement from the American Cancer Society Cancer

American Cancer Society Cancer Action Network (ACS CAN) volunteers will head to Capitol Hill today with over 100 other cancer patients, survivors, caregivers, physicians and researchers representing more than 50 cancer organizations to share poll results that show overwhelming public support for continued robust and sustained federal investment in cancer research and urge lawmakers to make fighting cancer a top national priority.

The law places limits on step therapy policies used by insurance companies that require patients to try less expensive, potentially less effective drugs before they can get coverage for the prescriptions their physicians recommend.